

ENANTA PHARMACEUTICALS INC  
Form 8-K  
March 06, 2019

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): February 28, 2019

ENANTA PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

Delaware 001-35839 04-3205099  
(State or other jurisdiction (Commission (IRS Employer

of incorporation) File Number) Identification No.)

500 Arsenal Street, Watertown, Massachusetts 02472

(Address of principal executive offices, including zip code)

(617) 607-0800

(Registrant's telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):

Written communications pursuant to rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17, CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

---

Item 5.07 Submission of Matters to a Vote of Security Holders.

At the annual meeting of stockholders held on February 28, 2019, Enanta's stockholders voted on the following proposals, each of which is described in detail in the Company's definitive proxy statement filed with the Securities and Exchange Commission on January 18, 2019.

Proposal No. 1: To Elect Two Class III Directors to Serve Until the 2022 Annual Meeting of Stockholders.

The stockholders re-elected the following individuals as Class III directors of the Company:

Name of Director Nominee	Votes For	Broker	
		Votes Withheld	Non-Votes
Stephen Buckley, Jr.	14,546,299	111,236	1,438,218
Lesley Russell	14,551,689	105,846	1,438,218

Proposal No. 2: To Approve the 2019 Equity Incentive Plan.

The stockholders approved the 2019 Equity Incentive Plan.

			Broker
Votes For	Votes		Non-Votes
	Against	Abstain	
8,719,605	5,927,973	9,957	1,438,218

Proposal No. 3: To Approve, on an Advisory Basis, the Frequency of Holding an Advisory Vote on the Compensation Paid to the Company's Named Executive Officers.

The stockholders approved the frequency of holding an advisory vote on compensation paid to the Company's named executive officers.

				Broker
Each Year	2 Years	3 Years	Abstain	Non-Votes
14,157,448	8,587	477,415	14,084	1,438,219

Proposal No. 4: To Approve, on an Advisory Basis, the Compensation Paid to the Company's Named Executive Officers.

The stockholders approved the advisory vote on executive compensation, or a "say-on-pay" vote.

Votes			Broker
Votes For	Against	Abstain	Non-Votes
14,439,535	195,192	22,807	1,438,219

Proposal No. 5: To Ratify the Appointment of PricewaterhouseCoopers LLP as Enanta's Independent Registered Public Accounting Firm for the 2019 Fiscal Year.

The stockholders ratified the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending September 30, 2019.

Votes			Broker
Votes For	Against	Abstain	Non-Votes
15,925,976	153,158	16,619	0

---

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: March 6, 2019 ENANTA PHARMACEUTICALS, INC.

By: /s/ Jay R. Luly, Ph.D.

Jay R. Luly, Ph.D.

Chief Executive Officer